News
Gilead, Glympse Bio collaborate on use of biomarker technology in NASH Clinical Development
Glympse Bio’s synthetic biomarkers will be used to determine clinical trial participants’ stage of disease to determine responses to treatment in Gilead’s NASH clinical program.
